Ligand Pharmaceuticals (LGND) Assets Average (2011 - 2026)

Ligand Pharmaceuticals (LGND) has 16 years of Assets Average data on file, last reported at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 67.43% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 67.43% YoY), and the FY2025 full-year result was $1.3 billion, up 44.73% from the prior year.
• Assets Average rose to $1.5 billion in Q1 2026, from $1.5 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.5 billion in Q1 2026 to a low of $763.7 million in Q3 2023.
• A 5-year average of $1.0 billion and a median of $923.6 million in 2025 frame the typical range for Assets Average.
• Across the five-year window, Assets Average plunged 34.5% in 2023 and soared 67.43% in 2026, its largest moves.
• Tracing LGND's Assets Average over 5 years: stood at $906.6 million in 2022, then slipped by 14.16% to $778.2 million in 2023, then advanced by 21.86% to $948.3 million in 2024, then jumped by 60.15% to $1.5 billion in 2025, then climbed by 1.82% to $1.5 billion in 2026.
• Business Quant data shows LGND's Assets Average at $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.2 billion in Q3 2025.